Evaluation of Late Clinical Events After Drug-eluting Versus Bare-metal Stents in Patients at Risk: BAsel Stent Kosten Effektivitats Trial - PROspective Validation Examination Part II (BASKET-PROVE II).

Trial Profile

Evaluation of Late Clinical Events After Drug-eluting Versus Bare-metal Stents in Patients at Risk: BAsel Stent Kosten Effektivitats Trial - PROspective Validation Examination Part II (BASKET-PROVE II).

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 05 Jun 2015

At a glance

  • Drugs Umirolimus (Primary) ; Aspirin; Everolimus; Prasugrel
  • Indications Coronary artery disease; Coronary artery restenosis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms BASKET-PROVE II
  • Most Recent Events

    • 24 Jan 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 24 Jan 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 02 Apr 2012 Planned end date (May 2014) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top